Predicting and implications of target volume changes of brain metastases during fractionated stereotactic radiosurgery.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
01 2020
Historique:
received: 20 11 2018
revised: 08 07 2019
accepted: 09 07 2019
pubmed: 23 8 2019
medline: 13 8 2020
entrez: 22 8 2019
Statut: ppublish

Résumé

To study the impact of target volume changes in brain metastases during fractionated stereotactic radiosurgery (fSRS) and identify patients that benefit from MRI guidance. For 15 patients (18 lesions) receiving fSRS only (fSRS Target volume changes during fSRS did result in large declines of the PTV dose coverage up to -34.8% (median = 3.2%) for fSRS Target volume changes in brain metastases during fSRS can result in worsening of the target dose coverage. Patients benefiting the most from a repeated MRI during treatment could be identified before treatment.

Identifiants

pubmed: 31431379
pii: S0167-8140(19)33001-4
doi: 10.1016/j.radonc.2019.07.011
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-179

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Eline Hessen (E)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Jasper Nijkamp (J)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Pim Damen (P)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Michael Hauptmann (M)

Department of Epidemiology and Biostatistics, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Bas Jasperse (B)

Department of Radiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Luc Dewit (L)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Lotte Lutkenhaus (L)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Emmy Lamers (E)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Uulke van der Heide (U)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Eugène Damen (E)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Patrick Hanssens (P)

Gamma Knife Center Tilburg, Tilburg, Netherlands.

Gerben Borst (G)

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands. Electronic address: g.borst@nki.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH